Similar articles for PMID: 20585076

Year	Number of Results
2007	1
2008	10
2009	35
2010	22
2011	1
2013	1
2019	1
2024	0

1

Prasugrel as a potential cancer promoter: review of the unpublished data.

Floyd JS, Serebruany VL. Floyd JS, et al. Arch Intern Med. 2010 Jun 28;170(12):1078-80. doi: 10.1001/archinternmed.2010.154. Arch Intern Med. 2010. PMID: 20585076 Review. No abstract available.

2

Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance.

Kaul S, Diamond GA. Kaul S, et al. Arch Intern Med. 2010 Jun 28;170(12):1010-2. doi: 10.1001/archinternmed.2010.139. Arch Intern Med. 2010. PMID: 20585063 No abstract available.

3

Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications.

Serebruany VL. Serebruany VL. Am J Med. 2009 May;122(5):407-8. doi: 10.1016/j.amjmed.2008.11.023. Am J Med. 2009. PMID: 19375544 No abstract available.

4

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.

[No authors listed] [No authors listed] Prescrire Int. 2009 Oct;18(103):193-5. Prescrire Int. 2009. PMID: 19877380

5

Prasugrel, a new platelet inhibitor.

Yee D, Meyer J, Caliendo G, Oviedo V. Yee D, et al. Mt Sinai J Med. 2010 May-Jun;77(3):315-23. doi: 10.1002/msj.20185. Mt Sinai J Med. 2010. PMID: 20506458 No abstract available.

6

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Capranzano P, Ferreiro JL, Angiolillo DJ. Capranzano P, et al. Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4. Expert Rev Cardiovasc Ther. 2009. PMID: 19379060 Review.

7

[Prasugrel--oral (Efient)].

[No authors listed] [No authors listed] J Pharm Belg. 2010 Dec;(4):131-2. J Pharm Belg. 2010. PMID: 21298816 French. No abstract available.

8

Smoking and prasugrel.

Ye Y, Xie H, Zhao X, Zhang S. Ye Y, et al. Int J Cardiol. 2013 Sep 30;168(2):1590-1. doi: 10.1016/j.ijcard.2013.01.042. Epub 2013 Feb 6. Int J Cardiol. 2013. PMID: 23395458 No abstract available.

9

Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial.

Capodanno D, Tamburino C. Capodanno D, et al. Int J Cardiol. 2011 Jan 21;146(2):242-3. doi: 10.1016/j.ijcard.2010.10.054. Epub 2010 Dec 3. Int J Cardiol. 2011. PMID: 21130510 No abstract available.

10

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.

Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E. Antman EM, et al. J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002. J Am Coll Cardiol. 2008. PMID: 18498956 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

64 results

Results by year